NVAX Novavax Inc

Price (delayed)

$237.54

Market cap

$17.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.89

Enterprise value

$16B

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
The revenue has grown by 29% from the previous quarter
NVAX's gross profit is up by 29% QoQ
Novavax's debt has increased by 34% YoY but it has decreased by 6% QoQ
Novavax's net income has plunged by 54% from the previous quarter
NVAX's quick ratio has dropped by 53% year-on-year and by 25% since the previous quarter

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
74.48M
Market cap
$17.69B
Enterprise value
$16B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
23.61
Price to sales (P/S)
14.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.54
Earnings
Revenue
$1.18B
EBIT
-$924.2M
EBITDA
-$670.63M
Free cash flow
$592.76M
Per share
EPS
-$13.89
Free cash flow per share
$8
Book value per share
$10.06
Revenue per share
$15.95
TBVPS
$35.21
Balance sheet
Total assets
$2.75B
Total liabilities
$2B
Debt
$430.32M
Equity
$745.56M
Working capital
$703.48M
Liquidity
Debt to equity
0.58
Current ratio
1.43
Quick ratio
1.33
Net debt/EBITDA
2.52
Margins
EBITDA margin
-56.7%
Gross margin
100%
Net margin
-80.4%
Operating margin
-78.8%
Efficiency
Return on assets
-48.2%
Return on equity
-150.9%
Return on invested capital
-1,459.5%
Return on capital employed
-84.2%
Return on sales
-78.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
0.11%
1 week
-1.92%
1 month
1.27%
1 year
105.64%
YTD
113.02%
QTD
11.88%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$1.18B
Gross profit
$1.18B
Operating income
-$931.26M
Net income
-$949.91M
Gross margin
100%
Net margin
-80.4%
Novavax's net margin has surged by 57% YoY but it has decreased by 20% QoQ
Novavax's operating income has plunged by 55% from the previous quarter
Novavax's net income has plunged by 54% from the previous quarter
The operating margin has soared by 53% year-on-year but it has declined by 20% since the previous quarter

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
23.61
P/S
14.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.54
Novavax's EPS has decreased by 47% QoQ
Novavax's equity has decreased by 28% QoQ
The stock's price to book (P/B) is 12% less than its last 4 quarters average of 26.9
The revenue has grown by 29% from the previous quarter
NVAX's P/S is 29% below its 5-year quarterly average of 21.1 and 19% below its last 4 quarters average of 18.4

Efficiency

How efficient is Novavax business performance
NVAX's return on assets has dropped by 107% year-on-year and by 19% since the previous quarter
Novavax's return on sales has surged by 51% YoY but it has decreased by 21% QoQ
Novavax's return on equity has decreased by 20% QoQ

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 37% higher than its total liabilities
Novavax's total assets has surged by 195% YoY and by 5% QoQ
NVAX's quick ratio has dropped by 53% year-on-year and by 25% since the previous quarter
Novavax's debt is 42% lower than its equity
NVAX's debt to equity has dropped by 67% year-on-year but it is up by 32% since the previous quarter
Novavax's debt has increased by 34% YoY but it has decreased by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.